GT Medical Technologies raises $100M Series E to advance brain tumour therapy. 9 June 2026 Key Takeaways * GT Medical Technologies raises $100 million Series E led by Viking Global Investors * Company advances BRIDGES RCT and commercial rollout after strong clinical results * Funding supports expansion of GammaTile brain tumour treatment and clinical trials GT Medical Technologies raises $100M to scale brain tumour innovation. GT Medical Technologies has raised $100 million in Series E funding. Viking Global Investors led the round. Several existing investors also participated. The round was oversubscribed. It reflects strong investor demand for medical device innovation. Total participation included MVM Partners, Gilde Healthcare, Evidity Health Capital, Medtech Venture Partners, and FemHealth Ventures. The company develops treatments for brain tumour patients. It focuses on improving survival outcomes and quality of life. Its flagship product is GammaTile therapy. Funds will support commercial expansion. They will also strengthen operational capacity. The company will accelerate clinical programmes and market rollout. GT Medical Technologies continues to position GammaTile as a potential standard of care. The therapy is designed for use during brain tumour surgery. It delivers immediate targeted radiation at the tumour site. GammaTile therapy shows strong clinical outcomes in trials. GammaTile is a bioresorbable collagen implant. It contains Cesium-131 radioactive seeds. Surgeons place it directly into the surgical cavity after tumour removal. The system delivers immediate radiation therapy. It targets remaining cancer cells at their lowest levels. It reduces risk of tumour regrowth. The treatment limits exposure to healthy brain tissue. Radiation is highly localised. This reduces side effects compared to external beam radiation. The tiles naturally dissolve in the body over time. Patients do not require a second surgery. It also removes the need for long daily hospital radiation visits. Clinical data has shown strong outcomes. The ROADS randomized controlled trial demonstrated significant improvement versus standard care. Tumour recurrence at 12 months dropped sharply. Survival outcomes also improved. Median time to recurrence was significantly extended. The therapy was selected for presentation at the 2026 ASCO conference. Results highlighted meaningful clinical advantages. The data strengthened confidence in broader adoption. The company is now expanding its BRIDGES RCT. This trial focuses on newly diagnosed glioblastoma patients. It aims to further validate treatment benefits. Investor confidence builds on breakthrough clinical data. GT Medical Technologies raises $100M to scale GammaTile brain tumour therapy and expand global clinical adoption. Source: Created by Ventureburn Viking Global Investors led the financing. The firm manages over $52 billion in capital. It invests across public and private markets globally. "We are excited to lead this financing," said Jason Rostovsky, Principal at Viking Global Investors. He highlighted GammaTile's clinical impact. He said the therapy shows strong potential in brain tumour treatment. He added that the company could reshape treatment standards. GT Medical Technologies said the round was oversubscribed. It described strong investor conviction in its platform. The company sees the funding as validation of its clinical progress. Chief Financial and Strategy Officer James Leech said the capital provides flexibility. He noted it enables accelerated clinical and operational investment. The company believes GammaTile can improve treatment pathways. It aims to reduce delays between surgery and radiation therapy. It also seeks to improve patient outcomes globally. Investor support reflects growing interest in precision oncology. Medical device innovation is attracting increasing capital inflows. The sector continues to expand rapidly. GT Medical Technologies is positioned within this shift. Its approach combines surgery and radiation in a single procedure. It reduces treatment complexity for patients. Expansion plans and commercial growth Strategy. The new funding will accelerate commercial expansion. GT Medical Technologies plans to scale operations across healthcare systems. It will also expand clinical partnerships. The company will invest in ongoing trials. The BRIDGES RCT remains a key focus. It targets glioblastoma patients with high unmet need. GT Medical Technologies aims to broaden adoption of GammaTile. It is working with surgical and oncology teams. It also focuses on regulatory and clinical engagement. The company expects continued demand growth. Strong clinical results support wider hospital adoption. It is also expanding operational infrastructure. GammaTile is designed to integrate into surgical workflows. It provides immediate post-surgery treatment. This removes delays in standard radiation schedules. The company is actively improving its platform. It plans to broaden the applicability to other tumor types and to have a wider application around the globe. The company management is committed to the thought that the treatment can set a new standard for the treatment of brain tumors. It focuses on optimizing survival benefits while minimizing the treatment burden. GT Medical Technologies is investing in a multi-year research effort and is accumulating evidence for broad clinical utility. Further expansion of clinical trials and increased commercial adoption are anticipated. To stay updated on crypto venture capital funding and market trends, visit its venture capital news section for more insights. Clinton Nwachukwu is a crypto and finance writer with an MBA in Artificial Intelligence and 6+ years of experience creating content for leading global brands. He turns complex topics into clear, actionable insights for readers worldwide. Disclaimer VentureBurn is a media platform covering the latest in cryptocurrency, artificial intelligence, venture capital, and the startup ecosystem. Opinions expressed on VentureBurn are for informational purposes only and do not constitute investment advice. Before making any high-risk investments in digital assets or emerging technologies, readers should conduct their own due diligence. All transactions and financial decisions are made at your own risk, and any losses incurred are solely your responsibility. VentureBurn does not endorse or recommend the buying or selling of any digital assets and is not a licensed investment advisor. Please note that VentureBurn may participate in affiliate marketing programs.

Pharma funding roundup: City Therapeutics closes $99.5 million Series B, Eloxx Pharmaceuticals announces pricing of $66 million public offering. City Therapeutics closed a $99.5 million Series B to push two RNAi programs into the clinic this year while Eloxx Pharmaceuticals raised $66 million alongside a Nasdaq uplisting to advance its nonsense mutation readthrough platform. Two RNA-focused biotechs secured fresh capital this week, as City Therapeutics closed a $99.5 million Series B to advance its RNAi pipeline and Eloxx Pharmaceuticals raised $66 million in a public offering tied to its Nasdaq uplisting. City Therapeutics closes Series B. City Therapeutics completed a $99.5 million Series B financing led by a syndicate that includes new investors Viking Global Investors and Sofinnova Investments, alongside Casdin Capital, NYBC Ventures, and existing backers including ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, and Regeneron Ventures.[1] Proceeds from the funding are expected to be used to advance the company's RNAi pipeline, accelerate its next-generation RNAi engineering platform, and support business development. City Therapeutics recently initiated a Phase I clinical trial of City-Fxi, an RNAi therapy targeting Factor XI for thromboembolic diseases, and has announced positive preclinical data for City-RBP4, a potentially first-in-class RNAi therapy for Stargardt disease, a rare inherited retinal condition. The company says it expects to advance two programs to clinical stage this year, including City-RBP4.[1] "With this capital, we are well-positioned to move two programs to clinical stage this year and continue to validate our innovative RNAi platform," said Andy Orth, chief executive officer of City Therapeutics. "We have achieved multiple important milestones in the two years since our Series A financing, including advancing CITY-FXI to the clinic and completing major strategic collaborations with Bausch + Lomb and Biogen." John Maraganore, PhD, co-founder and executive chairman of City Therapeutics, said the financing reflects the company's progress in expanding RNAi beyond its traditional applications. "Our innovative approach is expanding the reach of RNAi medicines into new programs and tissue types," he said. As part of the financing, Rohan Nirody of Viking Global Investors and Maha Radhakrishnan of Sofinnova Investments will join the City Therapeutics board of directors as observers.[1] Eloxx Pharmaceuticals prices $66 million offering. In other funding news, Eloxx Pharmaceuticals priced a public offering of approximately 6 million shares and pre-funded warrants at $11.00 per share, expecting to raise $66 million in gross proceeds before underwriting discounts and expenses.[2] The offering is expected to close on June 10, 2026, with shares beginning to trade on the Nasdaq Capital Market under the ticker "ELOX" on June 9. Eloxx is a clinical-stage company developing small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations, a mechanism that could enable production of full-length, functional proteins in diseases where a single genetic error disrupts protein expression.[2] The approach has broad potential applicability across rare genetic diseases driven by nonsense mutations. Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers for the offering, with LifeSci Capital serving as passive bookrunner. The capital raise and Nasdaq uplisting position Eloxx to advance its pipeline at a time when readthrough therapies are drawing increased attention as a platform approach to rare disease, particularly as gene editing and RNA-based modalities continue to validate the broader category of genetic medicine.[2]

GT Medical Technologies has closed an oversubscribed $100 million Series E equity financing led by new investor Viking Global Investors, with participation from existing backers including MVM Partners, Gilde Healthcare and Evidity Health Capital. The Tempe-based medical device company develops GammaTile, an FDA-cleared bioresorbable radiotherapy implant for brain tumours. The funding follows final data from the company's ROADS randomised controlled trial, presented at the 2026 ASCO conference, which showed GammaTile reduced the risk of tumour recurrence and death at 12 months by 93% and 41% respectively compared to standard care. Proceeds will accelerate commercial and operational initiatives and support expansion of GT Medical Technologies' BRIDGES trial in patients with newly diagnosed glioblastomas.